Pyr-T

Last updated
Pyr-T
Pyr-T.png
Names
Preferred IUPAC name
3-[2-(Pyrrolidin-1-yl)ethyl]-1H-indole
Other names
N,N-Tetramethylenetryptamine
Identifiers
3D model (JSmol)
ChemSpider
PubChem CID
UNII
  • InChI=1S/C14H18N2/c1-2-6-14-13(5-1)12(11-15-14)7-10-16-8-3-4-9-16/h1-2,5-6,11,15H,3-4,7-10H2 Yes check.svgY
    Key: CVTZCBLFHNGYDQ-UHFFFAOYSA-N Yes check.svgY
  • InChI=1/C14H18N2/c1-2-6-14-13(5-1)12(11-15-14)7-10-16-8-3-4-9-16/h1-2,5-6,11,15H,3-4,7-10H2
    Key: CVTZCBLFHNGYDQ-UHFFFAOYAE
  • c2c(c1ccccc1[nH]2)CCN3CCCC3
Properties
C14H18N2
Molar mass 214.312 g·mol−1
Melting point 193 to 194 °C (379 to 381 °F; 466 to 467 K) (HCl salt.)
Boiling point 170 to 180 °C (338 to 356 °F; 443 to 453 K) (Freebase at 0.05mm/Hg.)
log P 2.74410
Vapor pressure 1.02x10−5mmHg
Except where otherwise noted, data are given for materials in their standard state (at 25 °C [77 °F], 100 kPa).
X mark.svgN  verify  (what is  Yes check.svgYX mark.svgN ?)

Pyr-T (N,N-tetramethylenetryptamine) is a lesser-known, possible psychedelic drug. Pyr-T was first characterized by S. Mitzal. [1] Toxicity testing was later performed by Hunt and Brimblecombe, and although a lethal dosage was found in rats, a value is not given. [2] In the book TiHKAL (Tryptamines I Have Known and Loved), neither the dosage nor the duration are reported. [3] [4]

Pyr-T produces few to no effects in humans, but some behavioral changes were observed in animal tests. [2] Very little data exists about the pharmacological properties, metabolism, and toxicity of pyr-T.

See also

Related Research Articles

<span class="mw-page-title-main">4-HO-DiPT</span> Chemical compound

4-Hydroxy-N,N-diisopropyltryptamine is a synthetic psychedelic drug. It is a higher homologue of psilocin, 4-HO-DET, and is a positional isomer of 4-HO-DPT and has a tryptamine molecular sub-structure.

<i>N</i>-Methyl-<i>N</i>-ethyltryptamine Chemical compound

N-Methyl-N-ethyltryptamine (MET) is a psychedelic tryptamine. It is closely related to DMT and DET. The lysergamide counterpart of MET is ETH-LAD, an analogue of LSD first developed and characterized by Alexander Shulgin.

<span class="mw-page-title-main">DiPT</span> Chemical compound

Diisopropyltryptamine is a psychedelic hallucinogenic drug of the tryptamine family that has a unique effect. While the majority of hallucinogens affect the visual sense, DiPT is primarily aural.

<span class="mw-page-title-main">5-MeO-MiPT</span> Chemical compound

5-MeO-MiPT is a psychedelic and hallucinogenic drug, used by some as an entheogen. It has structural and pharmacodynamic properties similar to the drugs 5-MeO-DiPT, DiPT, and MiPT. It is commonly used as a "substitute" for 5-MeO-DiPT because of the very similar structure and effects.

<span class="mw-page-title-main">MiPT</span> Chemical compound

N-methyl-N-isopropyltryptamine (MiPT) is a psychedelic tryptamine, closely related to DMT, DiPT and miprocin. It was first synthesized by David Repke in 1984 and was subsequently evaluated and described in Alexander Shulgin's 1997 book TiHKAL.

<span class="mw-page-title-main">Ethylisopropyltryptamine</span> Chemical compound

Ethylisopropyltryptamine (EiPT) is a chemical of the tryptamine family that and produces psychedelic and hallucinogenic effects. It was probably first synthesized by American psychopharmacologist, Alexander Shulgin.

<span class="mw-page-title-main">Dibutyltryptamine</span> Chemical compound

N,N-Dibutyltryptamine (DBT) is a psychedelic drug belonging to the tryptamine family. It is found either as its crystalline hydrochloride salt or as an oily or crystalline base. DBT was first synthesized by the chemist Alexander Shulgin and reported in his book TiHKAL . Shulgin did not test DBT himself, but reports a human dosage of "1 mg/kg i.m." being active, but less so than DMT or DET. This suggests that an active dosage of DBT will be in the 100 mg range. This compound has been sold as a "research chemical" and has been confirmed to be an active hallucinogen although somewhat weaker than other similar tryptamine derivatives. It produces a head-twitch response in mice.

<span class="mw-page-title-main">2-Me-DET</span> Chemical compound

2-Me-DET, or 2-methyl-diethyltryptamine, is a lesser-known psychedelic drug. It is the 2-methyl analog of DET. 2-Me-DET was first synthesized by Alexander Shulgin. In his book TiHKAL, the minimum dosage is listed as 80-120 mg, and the duration listed as 6–8 hours. 2-Me-DET produces pitch distortion, like that of DiPT. Very little data exists about the pharmacological properties, metabolism, and toxicity of 2-Me-DET.

<span class="mw-page-title-main">Methylbutyltryptamine</span> Chemical compound

MBT, or N-methyl-N-butyltryptamine, is a lesser-known psychedelic drug. MBT was first synthesized by Alexander Shulgin. In his book TiHKAL, the minimum dosage is listed as 250-400 mg, and the duration listed as 4–6 hours. MBT produces a heavy body load with dehydration, and causes visuals similar to those of DMT. Very little data exists about the pharmacological properties, metabolism, and toxicity of MBT.

<span class="mw-page-title-main">4-HO-MET</span> Chemical compound

4-HO-MET is a lesser-known psychedelic drug. It is a structural and functional analog of psilocin as well as the 4-hydroxyl analog of methylethyltryptamine (MET). 4-HO-MET was first synthesized by Alexander Shulgin. In his book TiHKAL, the dosage is listed as 10-20 mg. 4-HO-MET produces psilocin-like distortion of color, sound, and form. Very little data exists about the pharmacological properties, metabolism, and toxicity of 4-HO-MET. There have been no reports of deaths from 4-HO-MET, even though there exist anecdotal reports of the ingestion of up to 150 mg, more than an order of magnitude above the effective dose.

<span class="mw-page-title-main">4-HO-MPT</span> Chemical compound

4-Hydroxy-N-methyl-N-propyltryptamine, commonly known as 4-HO-MPT or meprocin, is a psychedelic drug in the tryptamine class of chemical compounds and is a higher homologue of the naturally occurring substituted tryptamine psilocin as well as being the 4-hydroxyl analog of MPT.

<span class="mw-page-title-main">4-HO-pyr-T</span> Chemical compound

4-HO-pyr-T (4-hydroxy-N,N-tetramethylenetryptamine) is a lesser-known psychedelic drug. It is the 4-hydroxyl analog of pyr-T. 4-HO-pyr-T was first synthesized by Alexander Shulgin. In his book TiHKAL, neither the dosage nor the duration are reported. 4-HO-pyr-T produces few to no effects. Very little data exists about the pharmacological properties, metabolism, and toxicity of 4-HO-pyr-T.

<span class="mw-page-title-main">4-MeO-MiPT</span> Chemical compound

4-MeO-MiPT, or 4-methoxy-N-methyl-N-isopropyltryptamine, is a lesser-known psychedelic drug. It is the 4-methoxy analog of MiPT. 4-MeO-MiPT was first synthesized by Alexander Shulgin and is mentioned in his book TiHKAL. Subsequent testing by Shulgin on human test subjects showed the effective dose as 20-30 mg ; the onset time between ingestion and the first noticeable effects was 45-60 min, with sensations lasting between 2-2.5 hours. The sensation were significantly milder than those of 4-HO-MiPT, with 4-MeO-MiPT producing erotic-enhancing effects, and few of the visuals common with tryptamines. Very little data exists about the pharmacological properties, metabolism, and toxicity of 4-MeO-MiPT.

<span class="mw-page-title-main">5-MeO-pyr-T</span> Chemical compound

5-MeO-pyr-T (5-methoxy-N,N-tetramethylenetryptamine) is a lesser-known psychedelic drug. It is the 5-methoxy analog of pyr-T. 5-MeO-pyr-T was first synthesized by Hunt & Brimblecombe, who credited S. Mitzal for characterization of chemical properties. Later human tests were reported by Alexander Shulgin, in his book TiHKAL. An oral dosage of 0.5 to 2 mg, and an inhaled dosage of 2–3 mg are reported. 5-MeO-pyr-T causes varying reactions, such as amnesia, tinnitus, vomiting, and a 5-MeO-DMT-like rushing sensation. At the highest dosage reported in TiHKAL, the subject describes awakening from an apparent fugue state during which they were wandering the streets, with complete amnesia upon awakening.

<span class="mw-page-title-main">5-MeS-DMT</span> Chemical compound

5-MeS-DMT (5-methylthio-N,N-dimethyltryptamine) is a lesser-known psychedelic drug. It is the 5-methylthio analog of dimethyltryptamine (DMT). 5-MeS-DMT was first synthesized by Alexander Shulgin. In his book TiHKAL, the minimum dosage is listed as 15-30 mg. The duration listed as very short, just like DMT. 5-MeS-DMT produces similar effects to DMT, but weaker. Shulgin describes his feelings while on a low dose of this drug as "pointlessly stoned", although at a higher dose of 20 mg he says it is "quite intense" and suggests that a higher dose still might have full activity.

<span class="mw-page-title-main">5,6-MDO-DMT</span> Chemical compound

5,6-MDO-DMT, or 5,6-methylenedioxy-N,N-dimethyltryptamine, is a lesser-known psychedelic drug. It is the 5,6-methylenedioxy analog of DMT. 5,6-MDO-DMT was first synthesized by Alexander Shulgin. In his book TiHKAL, 5,6-MDO-DMT produces no noticeable psychoactive effects, although it was only tested up to a dose of 5 mg. Very little data exists about the pharmacological properties, metabolism, and toxicity of 5,6-MDO-DMT.

<span class="mw-page-title-main">5,6-MDO-DiPT</span> Chemical compound

5,6-MDO-DiPT, or 5,6-methylenedioxy-N,N-diisopropyltryptamine, is a lesser-known psychedelic drug. It is the 5,6-methylenedioxy analog of DiPT. 5,6-MDO-DiPT was first synthesized by Alexander Shulgin. It is mentioned in his book TiHKAL, but 5,6-MDO-DiPT was never tested to determine what effects it produces, if any. Very little data exists about the pharmacological properties, metabolism, and toxicity of 5,6-MDO-DiPT.

<span class="mw-page-title-main">2,α-Dimethyltryptamine</span> Chemical compound

2,α-Dimethyltryptamine (2,α-DMT) is a tryptamine and a lesser-known psychedelic drug. It is the 2,α-dimethyl analog of DMT. Its synthesis was first reported in 1965. Alexander Shulgin lists the dosage as 300-500 mg, and the duration as 7–10 hours in his book TiHKAL. 2,α-DMT causes mydriasis and paresthesia. It also produces a calm, drunk-like feeling. Very little data exists about the pharmacological properties, metabolism, and toxicity of 2,α-DMT.

α,<i>N</i>-DMT Chemical compound

α,N-Dimethyltryptamine (α,N-DMT; developmental code names SK&F-7024, Ro 3-1715), also known as N-methyl-α-methyltryptamine (N-methyl-αMT), is a lesser-known substituted tryptamine and psychoactive drug. It is the α,N-dimethyl positional isomer of N,N-dimethyltryptamine (N,N-DMT).

α,<i>N</i>,<i>O</i>-TMS Chemical compound

α,N,O-TMS, or α,N-dimethyl-5-methoxytryptamine, is a lesser-known psychedelic drug. Its abbreviated nomenclature is derived from its structure, as it is α,N,O-trimethyl serotonin. α,N,O-TMS was first synthesized by Alexander Shulgin. In his book TiHKAL, Shulgin lists the dosage as 10-20 mg when taken orally, and the duration as 6–8 hours.

References

  1. Mitzal, S. (1962). "N/A". Dissertationes Pharm. 14: 305.
  2. 1 2 Hunt, R. R.; Brimblecombe, R. W. (July 1967). "Synthesis and Biological Activity of Some Ring-Substituted Tryptamines". Journal of Medicinal Chemistry. 10 (4): 646–648. doi:10.1021/jm00316a027. PMID   4962512.
  3. Shulgin, Alexander; Shulgin, Ann (1997). TiHKAL, The Continuation (1st ed.). Berkeley, CA, USA: Transform Press. pp. 577–578. ISBN   0-9630096-9-9 . Retrieved 7 April 2018.
  4. Krasowski, Matthew D.; Ekins, Sean (2014). "Using cheminformatics to predict cross reactivity of "designer drugs" to their currently available immunoassays". Journal of Cheminformatics. 6: 22. doi: 10.1186/1758-2946-6-22 . PMC   4029917 . PMID   24851137.